The inhibitor WNT974 was studied in combination with encorafenib and cetuximab in a phase Ib/II trial of patients with BRAF V600E mutated, KRAS wild type metastatic colorectal cancer [37]. Here, BRAF is linked to metastatic colorectal cancer.